Results 31 to 40 of about 12,023 (229)

Medical treatment of Cushing's syndrome: Adrenal-blocking drugs and ketaconazole [PDF]

, 2010
Cushing's syndrome is associated with serious morbidity and increased mortality. Irrespective of its cause, i.e. a pituitary adenoma, ectopic ACTH production or an adrenal neoplasia, Cushing's syndrome is primarily treated surgically.
Feelders, R.A. (Richard), Herder, W.W. (Wouter) de, Hofland, L.J. (Leo)   +2 more
core   +9 more sources

Análise de custo-efetividade de análogos da somatostatina no tratamento de acromegalia no Brasil [PDF]

, 2008
This study aims to compare economic and patient impacts of the treatment of acromegaly with two different somatostatin analogues (octreotide LAR and lanreotide SR) in Brazil. A cost-effectiveness analysis was carried out under the Brazilian Public Health
CALABRÓ, Alessandra, MATAVELI, Fabio, PASSOS, Vanessa, VALENTIM, Joice   +3 more
core   +3 more sources

A middle cerebral artery ischemic stroke occurring in a child with a large prolactinoma. [PDF]

, 2020
Pituitary adenomas are rare in children, and often present with symptoms of headache, nausea or emesis, visual disturbance, or hormonal hypersecretion.
Amara, Dominic, Clerkin, Patricia, Gupta, Nalin, Oh, Taemin   +3 more
core  

The pituitary TGFb1 system as a novel target for the treatment of resistant prolactinomas [PDF]

, 2016
Prolactinomas are the most frequently observed pituitary adenomas and most of themrespond well to conventional treatment with dopamine agonists (DAs).
Camilletti, María Andrea, Diaz, Graciela Susana, Recouvreux, Maria Victoria, Rifkin, Daniel B.   +3 more
core   +2 more sources

Cabergoline vs intravenous albumin or combination of both for prevention of the early onset ovarian hyperstimulation syndrome

Middle East Fertility Society Journal, 2011
Background: Prophylactic use of dopamine agonist has been associated with a decrease in the severity of ovarian hyperstimulation syndrome (OHSS). Objective: To compare cabergoline with cabergoline plus I.V albumin or I.V albumin alone in prevention of ...
Badeea S. Soliman
doaj   +1 more source

De Novo Psychiatric Disorders in a Woman With Giant Prolactinoma Treated With Cabergoline

Clinical Medicine Insights: Case Reports, 2023
Dopamine agonists are the first-line treatment of prolactinomas. The risk of developing de novo psychiatric symptoms during dopamine agonist therapy is low.
Chayma Belhadj Slimane, Ibtissem Oueslati, Meriem Yazidi, Elyes Kamoun, Melika Chihaoui   +4 more
doaj   +1 more source

Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome [PDF]

, 2008
Somatostatin (SS) and dopamine (DA) receptors are widely expressed in neuroendocrine tumours that cause Cushing's Syndrome (CS). Increasing knowledge of specific subtype expression within these tumours and the ability to target these receptor subtypes ...
A Colao, A Colao, A Newman-Tancredi, A Saiardi, A Saveanu, A Saveanu, A Schonbrunn, AB Atkinson, AM Isidori, AM O’Carroll, AS Mahmoud-Ahmed, B Ambrosi, B Ueberberg, C Bruns, C Garcia, C Invitti, C Missale, C Missale, C. de Bruin, D Cervia, D Cervia, D Ferone, D Gaitan, D Morris, D Yin, DC Danila, DL Batista, DN Orth, DW Ray, E Mezey, F Amenta, F Castinetti, F Illouz, F Kelestimur, F Vignati, G Giustina, G Weckbecker, GI Uwaifo, GK Stalla, HA Schmid, HA Schmid, HL Fehm, I Ilias, I Shraga-Slutzky, J Hoek van der, J Hoek van der, J Jagannathan, J Kraicer, J Lindholm, J Newell-Price, J Stack, JB Tyrrell, JC Reubi, JM Farah Jr., JW Miller, KD Wu, L Petrini, L Stefaneanu, L. J. Hofland, LA Casulari, LJ Hofland, LJ Hofland, LJ Hofland, LK Nieman, M Locatelli, M Phlipponneau, M Rocheville, M Tallent, ME Molitch, ML Vance, MR Brown, MZ Strowski, N Unger, N Unger, P Barnett, P Brazeau, P Jaquet, P Jaquet, P Ma, P Petrossians, PJ Stafford, R Day, R Hall, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Pivonello, R Schade, R Zanettini, R. A. Feelders, RJ Benveniste, RJ Croughs, S. W. J. Lamberts, SL Lightman, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, SW Lamberts, T Antakly, T Miyoshi, UI Richardson, VG Rasmussen, WE Farrell, WW Herder de, WW Herder de, X Bertagna, YC Patel   +115 more
core   +4 more sources

Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma

Endocrine Oncology, 2023
Cabergoline-associated valvulopathy (CAV) is defined by the echocardiographic triad of moderate or severe regurgitation, valvular thickening and restricted valvular motion.
Annabelle G Hayes, Masoumeh G Shirazi, Anand Thiyagarajah, David J Torpy, Sunita M C De Sousa   +4 more
doaj   +1 more source

Novel Medicine for Endometriosis and Its Therapeutic Effect in a Mouse Model

Biomedicines, 2020
Current therapeutic medicines for endometriosis cannot be administered during assisted reproductive technology (ART) because they have bad effects during pregnancy.
Young Sang Kim, Yu Jin Kim, Myung Joo Kim, Sang Jin Lee, Hwang Kwon, Jae Ho Lee   +5 more
doaj   +1 more source

Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection [PDF]

International Journal of Fertility and Sterility, 2018
Background The aim of the current study is to compare quinagolide with cabergoline in prevention of ovarian hyperstimulation syndrome (OHSS) among high risk women undergoing intracytoplasmic sperm injection (ICSI).
Robabeh Taheripanah, Mahshid Vasef, Marzieh Zamaniyan, Anahita Taheripanah   +3 more
doaj   +1 more source